WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Suspect in London sword attack appears in court on murder charge in death of teenage boyTheme park operator offers holiday treatsChina urges universities to add majors that meet social needsRefugee Team for Paris Olympics has 36 athletes from 11 countries across 12 sportsHouse committee delays vote on bill to allow inmates to participate in parole hearingsIt would take until 2040 to repair all homes destroyed so far in Gaza, UN report saysDomestic theme parks see surging visits during Spring FestivalMedia forum in Beijing discusses AI developmentImmersive tours boost growth in China's tourismRoads, trains and planes to be crowded during holiday
3.007s , 6501.71875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Grandstand news portal